In an industry-first convergence of quantum photonics and precision medicine, INmune Bio Inc. (NASDAQ: INMB) and Quantum Computing Inc. (NASDAQ: QUBT) have entered into a commercial collaboration to apply quantum optimization, artificial intelligence, and advanced analytics to drug discovery.
The joint effort aims to analyze vast biological datasets to identify new therapeutic targets and predictive response biomarkers for XPro (XPro1595), INmune Bio's targeted biologic currently being evaluated for Alzheimer's disease and other neuroinflammatory disorders.